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Introduction
Organs are composed of highly differentiated, very specialized parenchymal cells surrounded by a stroma consisting of extracellular matrix (ECM), including collagens, glycoproteins, glycosaminoglycans and proteoglycans, tissue fluid, and undifferentiated, pluripotent mesenchymal cells. Fibrosis (or sclerosis) is defined as increased collagen concentration of an organ and consists predominantly of fibrillar collagen type(s) I and/or III. Collectively, fibrosis is a common pathway to organ failure. This holds true for such diverse organs as the heart and the kidney [1] .
Matrix metalloproteinases (MMPs), collectively called matrixins, are proteinases that participate in the degradation of collagens and other components of the ECM [2 . . ,3
. .
]. Under normal physiological conditions, the activities of MMPs are precisely regulated at several levels, including inhibition by endogenous inhibitors. Tissue inhibitors of metalloproteinases (TIMPs) are specific inhibitors of MMPs that participate in controlling the local activities of these enzymes in tissues [2 . . ,3
]. The interactions of MMPs and TIMPs that participate in hypertension-induced renal fibrosis and vascular sclerosis have been reviewed recently elsewhere [4 . ,5 . ]. In this review, we give an overview of the potential involvement of the interplay of MMPs and TIMPs in myocardial fibrosis present in subjects with hypertensive heart disease (HHD), here defined as the presence of left ventricular hypertrophy in the absence of a cause other than arterial hypertension. 
General aspects of matrix metalloproteinases and tissue inhibitors of metalloproteinases

Myocardial fibrosis in hypertensive heart disease
A growing body of evidence indicates that besides cardiomyocyte hypertrophy, myocardial fibrosis is one of the key pathological features of HHD (Fig. 1) . In fact, a number of studies performed in postmortem human hearts [13] [14] [15] and endomyocardial human biopsies [16] [17] [18] [19] [20] have shown that the amount of fibrillar collagen is constantly increased in the myocardium of patients with HHD compared with normotensive controls. The section was stained with picrosirius red, and the interstitial collagen was identified in red.
As in other organs, fibrillar collagen turnover in the normal adult heart results from the equilibrium between the synthesis and degradation of collagen types I and III molecules [21] . Thus, the current view is that myocardial fibrosis may be the consequence of the loss of reciprocal regulation that normally exists between collagen synthesis and degradation [22] (Fig. 2) . Although it is well accepted that chronic pressure overload leads to excessive collagen deposition and fibrosis [23] , recent clinical findings suggest that non-hemodynamic factors may also play a role [14, [24] [25] [26] [27] [28] . Thus, an excess of humoral factors that facilitate the synthesis of fibrillar collagen and/or a deficit of humoral factors that facilitate its degradation may contribute to fibrosis in HHD (Table 2) .
Several arguments (reviewed in [29] ) support the concept that myocardial fibrosis has an important influence on the transition from compensated left ventricular hypertrophy to heart failure in subjects with hypertension. Interstitial fibrosis, in particular, leads to ventricular wall stiffness and consequently impairs cardiac compliance, contributing to impaired diastolic function.
Alterations in matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with hypertensive heart disease
Clinical studies have shown that serum concentrations of free MMP-1 are reduced [30, 31 . ], whereas serum concentrations of free TIMP-1 are increased [30, 31 . -33 . ] or unchanged [34] in patients with HHD ( Fig. 3 [30] ). In addition, serum concentrations of the gelatinases MMP-2 and MMP-9 have been reported as reduced or unchanged in patients with HHD compared with normotensive controls [34, 35 . ]. In studies analyzing serum indices of collagen type I synthesis (carboxy-terminal propeptide of procollagen type I) and degradation (carboxy-terminal telopeptide of collagen type I) in patients with HHD, it was found that whereas the former was abnormally increased, the serum concentration of the latter remained unchanged or decreased slightly [36] . Collectively, these data suggest that extracellular degradation of fibrillar collagen is depressed in patients with HHD. This was confirmed at the cardiac level by Brilla et al. [37] , who reported that MMP-1 activity was depressed in the hypertrophied left ventricle of patients with hypertension.
On the other hand, it was recently reported that elevated serum TIMP-1 concentrations show good specificity and positive predictive value for detecting diastolic dysfunction among untreated patients with HHD [32 . ]. Another study has reported that the altered relationship between circulating MMP-1 and TIMP-1 is associated with atrial fibrillation in these patients [31 . ].
The effects of antihypertensive treatment on MMPs and TIMPs have been investigated in some clinical studies. Laviades et al. [34] demonstrated that serum concentrations of free TIMP-1 were reduced and that free MMP-1 concentrations were increased in patients with HHD after 1 year of treatment with the angiotensin-converting enzyme inhibitor lisinopril. Zervoudaki et al. [35] showed that patients with hypertension treated for 6 months with the calcium channel blocker amlodipine attained a non-significant increase in MMP-2 concentrations but a significant increase in MMP-9 plasma concentrations compared with respective values before treatment. By contrast, it has also been reported that levels of MMP-9 and TIMP-1 were not significantly altered after 2 months of treatment with lisinopril or with the angiotensin II type 1 receptor antagonist losartan, despite a significant decrease in blood pressure [37] .
Mechanisms of altered cardiac matrix metalloproteinase-1/tissue inhibitor of metalloproteinase-1 balance by pressure overload Nagatomo et al. [38] investigated myocardial MMP-1 and TIMP-1 expression in dogs subjected to chronic pressure overload secondary to aortic banding. With prolonged pressure overload, MMP-1 levels were reduced and TIMP-1 levels were unchanged. In addition, MMP-1/TIMP-1 complex formation was higher, suggesting that increased MMP-1 inhibition was operating in this overload state. These results suggest that myocardial MMP-1 activity can be modulated by physical stimuli (e.g. changes in cell shape and cytoskeletal disruption) in the hemodynamically overloaded heart. This possibility is supported by in-vitro findings showing that MMP-1 expression is inhibited in cardiac fibroblasts subjected to cyclic stretching [23] .
Alternatively, receptor-mediated effects on MMP-1 expression may also occur in the pressure-overloaded heart. In this regard, various lines of evidence support a role for angiotensin II as a humoral factor that inhibits collagen degradation pathways via interaction with the angiotensin II type 1 receptor [39 . . ]. Angiotensin II stimulation of the angiotensin II type 1 receptor has been shown to reduce collagen degradation by attenuating MMP-1 activity in adult rat [40] and human [41] cardiac fibroblasts and by enhancing TIMP-1 production in rat heart endothelial cells [42] . On the other hand, it has been found that chronic angiotensin II type 1 receptor antagonism with losartan results in reversal of fibrosis, stimulation of MMP-1 activity and inhibition of TIMP-1 expression in the left ventricle of adult spontaneously hypertensive rats [43] . Analysis of the individual data shows that the intensity of these changes is independent of the antihypertensive efficacy of the drug. Recently, it has been reported that the A 1166 C polymorphism of the The available data suggest that several factors may mediate the inhibitory effect of angiotensin II on cardiac collagen degradation. In fact, angiotensin II stimulates transforming growth factor-b 1 in cardiac fibroblasts [45] , where this factor inhibits MMP-1 and stimulates TIMP-1 [46, 47] . Similar findings have been reported in the myocardium of transforming growth factor-b 1 transgenic mice [48] . On the other hand, angiotensin II also stimulates plasminogen activator inhibitor-1 in cardiac fibroblasts [49] . This stimulatory effect has been confirmed in the left ventricle of angiotensin II-induced hypertensive rats [50] . Plasminogen activator inhibitor-1 inhibits the activation of MMP-1 and, thus, collagen degradation [51, 52] . Although it has been proposed that aldosterone contributes to angiotensin II-mediated myocardial fibrosis in HHD [53 . ], in-vitro studies show that this mineralocorticoid does not modify MMP-1 activity in cardiac fibroblasts [54] .
Do some matrix metalloproteinases contribute to fibrosis?
MMPs not only play a role in the degradation of matrix components, but also may participate in the fibrosis process, through two mechanisms [55] (Fig. 4) . MMPs may release factors that are associated with components of the ECM or cell membrane and that facilitate the synthesis of collagen relative to its degradation (Table 2) [56] . A variety of growth factors have been found to be associated with particular components of the ECM: transforming growth factor-b 1 with collagen type IV and fibronectin, basic fibroblast growth factor with collagen type III, platelet-derived growth factor with osteonectin, and insulin-like growth factor-1 with multiple insulinlike growth factor binding proteins.
In addition to growth factors, MMPs may release matrikines. MMP-1 initiates the digestion of collagens by hydrolyzing the peptide bond following a Gly residue located at a distance of three-quarters of the collagen molecule length from the amino terminus [57] . The resulting three-quarters and one-quarter fragments are completely degraded by MMP-2, MMP-3 and MMP-9. The final fragmented matrix peptides or matrikines have biological activities in the regulation of collagen tissue activity. For instance, the tripeptide glycyl-histidyllysine derived from several collagen proteins (including collagen a2(I), a2(V), a2(IX) chains) stimulates new collagen synthesis by fibroblasts [58] . It has been also shown that this tripeptide stimulates MMP-2 expression and secretion by fibroblasts in culture [59] , suggesting a redundant and cooperative role among some MMPs and matrikines.
The potential relevance of these interactions is given by several observations. The increase in myocardial fibrosis Small telopeptide that accompanies the transition from compensated hypertrophy to heart failure in Dahl salt-sensitive rats with hypertension is associated with increased MMP-2 messenger RNA and protein levels and activity [60] . Increased activities of MMP-2 and MMP-9, rather than reduced activity of MMP-1, have been reported in the fibrotic kidney of rats with spontaneous hypertension [61 . ]. Fibrosis of the left atria in a rat model of myocardial infarction complicated by left ventricular dysfunction and atrial dilatation is associated with increased expression of MMP-2 in the interstitial space of the atria [62 . ]. Finally, as mentioned before, treatment with amlodipine has been found to be associated with increased circulating levels of MMP-9 and a tendency to increased concentrations of MMP-2 in patients with HHD [36] . Interestingly, it has been reported in patients with HHD that chronic treatment with amlodipine was associated with a trend towards increased myocardial collagen content [28] .
Which factors might be responsible for this specific pattern of MMP activity in hypertension? One possibility is that MMPs involved in the generation of matrikines are stimulated by those mechanical and humoral factors that are activated in a heart subjected to chronic pressure overload. It has been shown that mechanical stretch [63] , stimulation with either angiotensin II or endothelin-1 [10] and oxidant stress [64] enhance MMP-2 and MMP-9 expression and activity in cardiovascular cells in culture. Thus, both the activity of these MMPs and the collagen content have been reported to decrease in the hearts of animals treated with an angiotensin-converting enzyme inhibitor [65] , an endothelin A receptor antagonist [65, 66] , or an antioxidant compound [67] . Another possibility is that profibrotic MMPs are under genetic control. In this regard, in the promoter of MMP-2, polymorphisms have been identified that appear to influence MMP-2 gene expression [68 . ].
Whatever the mechanism modulating MMP-2, MMP-9 and MMP-3 activity is, it represents a new potential therapeutic target in the context of hypertensive myocardial fibrosis. To date, active non-selective MMP inhibitors have been developed, but they have serious limitations because of their broad spectrum of inhibitory ability [69] . Therefore, an important area of future research is the development of selective inhibitors designed to achieve inhibition of the above profibrotic MMPs.
Conclusion
Arterial hypertension is accompanied by alterations in the balance between MMP-1 and TIMP-1 and by dysregulation of other MMPs, namely gelatinases, which may contribute to the exaggerated deposition of collagen fibers and fibrosis present in HHD. In turn, myocardial fibrosis may result in eventual heart failure and cardiovascular disability and death in patients with hypertension. The elucidation of the precise mechanisms that contribute to the selective induction of some MMP species within the hypertensive myocardium, as well as strategies for normalizing the balance between MMP-1 and TIMP-1, may yield some therapeutic approaches for controlling myocardial fibrosis, thereby preventing or slowing the transition from compensated left ventricular hypertrophy to heart failure in patients with arterial hypertension.
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